SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

2/6/24 4:01:34 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CRDF alert in real time by email

SC 13G/A 1 p24-0480sc13ga.htm CARDIFF ONCOLOGY, INC.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

Cardiff Oncology, Inc.
(Name of Issuer)

Common Stock, $0.0001 par value per share
(Title of Class of Securities)

14147L108
(CUSIP Number)

December 31, 2023
(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

(Page 1 of 8 Pages)

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 14147L108

13G/A

Page 2 of 8 Pages

1	NAME OF REPORTING PERSON Acorn Bioventures, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.20%
12	TYPE OF REPORTING PERSON PN

* Includes (i) 482,160 Series M Warrants and (ii) 1,229,506 Series N Warrants, which are exercisable for shares of Common Stock.

CUSIP No. 14147L108

13G/A

Page 3 of 8 Pages

1	NAME OF REPORTING PERSON Acorn Capital Advisors GP, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.20%
12	TYPE OF REPORTING PERSON OO

* Includes (i) 482,160 Series M Warrants and (ii) 1,229,506 Series N Warrants, which are exercisable for shares of Common Stock.

CUSIP No. 14147L108

13G/A

Page 4 of 8 Pages

1	NAME OF REPORTING PERSON Anders Hove
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,946,762 (including 1,711,668 shares of Common Stock issuable upon exercise of warrants)*
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.20%
12	TYPE OF REPORTING PERSON IN

* Includes (i) 482,160 Series M Warrants and (ii) 1,229,506 Series N Warrants, which are exercisable for shares of Common Stock.

CUSIP No. 14147L108

13G/A

Page 5 of 8 Pages

Item 1(a).	Name of Issuer.

	Cardiff Oncology, Inc. (the "Issuer")

Item 1(b).

Address of Issuer's Principal Executive Offices.

11055 Flintkote Avenue

San Diego, California 92121

Item 2(a).	Name of Person Filing.

	This statement is filed by:

	(i)	Acorn Bioventures, L.P. (“Acorn”);
	(ii)	Acorn Capital Advisors GP, LLC (“Acorn GP”), which is the sole general partner of Acorn; and
	(iii)	Anders Hove (“Hove”), who is the manager of Acorn GP.

	The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

	The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

Item 2(b).	Address of Principal Business Office.

	The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170

Item 2(c).	Place of Organization.

	Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Hove is a citizen of the United States of America.

Item 2(d).	Title of Class of Securities.

	Common stock, $0.0001 par value per share (the "Common Stock")

Item 2(e).	CUSIP Number.

	14147L108

CUSIP No. 14147L108

13G/A

Page 6 of 8 Pages

Item 3.

If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	¨	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	¨	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	¨	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	o	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	¨	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)	¨	Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution: __________________________

Item 4.	Ownership.

	The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

	The percentages set forth herein are calculated based on 44,677,169 shares of the Company’s common stock, par value $0.0001 per share outstanding as of October 26, 2023, as set forth in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 and filed with the Commission on November 2, 2023, and assumes the exercise of the reported warrants.

	Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn.

	Hove, in his capacity as the manager of Acorn GP, may be deemed to beneficially own the shares beneficially owned by Acorn.

CUSIP No. 14147L108

13G/A

Page 7 of 8 Pages

Item 5.	Ownership of Five Percent or Less of a Class.

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

Item 6.	Ownership of More Than Five Percent on Behalf of Another Person.

	Not applicable.

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

	Not applicable.

Item 8.	Identification and Classification of Members of the Group.

	Not applicable.

Item 9.	Notice of Dissolution of Group.

	Not applicable.

Item 10.	Certification.

	By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 14147L108

13G/A

Page 8 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 6, 2024
	ACORN BIOVENTURES, L.P.
	By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner

	By:	/s/ Anders Hove
	Name: Anders Hove
	Title: Manager


	ACORN CAPITAL ADVISORS GP, LLC

	By:	/s/ Anders Hove
	Name: Anders Hove
	Title: Manager


	ANDERS HOVE

	/s/ Anders Hove

Get the next $CRDF alert in real time by email

Date	Price Target	Rating	Analyst
9/6/2024	$8.00	Buy	Craig Hallum
2/28/2022	$26.00 → $25.00	Buy	HC Wainwright & Co.
1/5/2022		Outperform	William Blair
12/8/2021	$19.00	Outperform	Robert W. Baird
12/8/2021	$19.00	Outperform	Baird
8/10/2021	$25.00 → $26.00	Buy	HC Wainwright & Co.
8/9/2021	$30.00 → $20.00	Buy	Maxim Group

SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $CRDF

$CRDF Financials

Live finance-specific insights

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

$CRDF Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Craig Hallum initiated coverage on Cardiff Oncology with a new price target

HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

William Blair initiated coverage on Cardiff Oncology

$CRDF Large Ownership Changes

This live feed shows all institutional transactions in real time.